April 6, 2017 / 7:20 AM / 4 months ago

BRIEF-Photocure to assess further strategic alternatives for its non-urology assets, Cevira and Visonac

1 Min Read

April 6 (Reuters) - PHOTOCURE ASA:

* SAID ON WEDNESDAY WOULD ASSESS FURTHER STRATEGIC ALTERNATIVES FOR ITS NON-UROLOGY ASSETS, CEVIRA AND VISONAC, IN PARALLEL WITH ONGOING PARTNER SEARCH

* SAID WOULD FOCUS ON ITS UROLOGY FRANCHISE AND ITS CONTINUED COMMITMENT TO DRIVING GROWTH, PARTICULARLY IN THE UNITED STATES

* REMAINING DEVELOPMENT RISK IS EXPRESSED AS A CONCERN FOR ESTABLISHING AN OPTIMAL PARTNERSHIP FOR CEVIRA, WHILE THE CURRENT COMBINATION OF DRUG AND DEVICE IS AN EXPRESSED COMMERCIAL CONCERN FOR VISONAC

* HAS AN AMBITION TO QUADRUPLE THE U.S. REVENUES TO USD 15 MILLION BY 2020

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below